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Selective Detection of Histologically
Aggressive Prostate Cancer
An Early Detection Research Network Prediction Model to Reduce Unnecessary Prostate Biopsies
With Validation in the Prostate Cancer Prevention Trial
Stephen B. Williams, MD1,2,3; Simpa Salami, MD, MPH1; Meredith M. Regan, ScD3,4; Donna P. Ankerst, PhD5;
John T. Wei, MD6; Mark A. Rubin, MD7; Ian M. Thompson, MD5; and Martin G. Sanda, MD1,3
BACKGROUND: Limited survival benefit and excess treatment because of prostate-specific antigen (PSA) screening
in randomized trials suggests a need for more restricted selection of prostate biopsy candidates by discerning risk of
histologically aggressive versus indolent cancer before biopsy. METHODS: Subjects undergoing first prostate biopsy
enrolled in a multicenter, prospective cohort of the National Cancer Institute Early Detection Research Network (N ¼
635) were analyzed to develop a model for predicting histologically aggressive prostate cancers. The control arm of
the Prostate Cancer Prevention Trial (N ¼ 3833) was used to validate the generalization of the predictive model.
RESULTS: The Early Detection Research Network cohort was comprised of men among whom 57% had no cancer,
14% had indolent cancer, and 29% had aggressive cancer. Age, body mass index, family history of prostate cancer,
abnormal digital rectal examination (DRE), and PSA density (PSAD) were associated with aggressive cancer (all P <
.001). The Early Detection Research Network model outperformed PSA alone in predicting aggressive cancer (area
under the curve [AUC] ¼ 0.81 vs 0.71, P < .01). Model validation in the Prostate Cancer Prevention Trial cohort accu-
rately identified men at low (<10%) risk of aggressive cancer for whom biopsy could be averted (AUC ¼ 0.78; 95%
confidence interval, 0.75-0.80). Under criteria from the Early Detection Research Network model, prostate biopsy
can be restricted to men with PSAD >0.1 ng/mL/cc or abnormal DRE. When PSAD is <0.1 ng/mL/cc, family history or
obesity can identify biopsy candidates. CONCLUSIONS: A predictive model incorporating age, family history, obesity,
PSAD, and DRE elucidates criteria whereby 1=4 of prostate biopsies can be averted while retaining high sensitivity in
detecting aggressive prostate cancer. Cancer 2012;118:2651-58. VC 2011 American Cancer Society.
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INTRODUCTION
Prostate -specific antigen (PSA) screening has led to a significant increase in detection of clinically localized T1c
prostate cancer with concomitant stage migration,1,2 and results from randomized trials of PSA screening have revealed
limited to no survival benefit when simple PSA cutoffs were used for recommendation for or against prostate biopsy.3,4
These findings have raised questions as to whether strategies based simply on PSA and age cutoffs are sufficient for identi-
fying suitable candidates for prostate biopsy when the ultimate goal of early detection is to identify aggressive disease that
harbors lethal potential and yet is amenable to definitive treatment.
The ability to discern aggressive from indolent prostate cancer is a centerpiece of current efforts underway to refine prostate
cancer detection, decisionmaking, and care. Epstein et al identified histological criteria in prostate biopsy specimens that discrim-
inate indolent from clinically significant prostate cancer.5 As originally described, the histological criteria that define indolent dis-
ease on prostate biopsy include absence of Gleason pattern 4 or 5, cancer limited to 3 or fewer biopsy cores, and<50% tumor
involvement in any individual core. Prospective studies have used these criteria to define eligibility for active surveillance.6-8
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Prior studies have used findings from biopsy to assess
risk of indolent cancer at prostatectomy,9-11 but predictive
tools to discern risk of aggressive versus indolent cancer
before a patient undergoes prostate biopsy have not been
extensively characterized. The Prostate Cancer Prevention
Trial calculator facilitates individual assessment of prostate
cancer risk in general and specific risk of high-grade disease
for men who undergo a prostate biopsy,12 but does not dis-
cern the possibility of aggressive Gleason score 6 cancers, a
limitation also inherent in a separate predictive nomogram
developed based on a single-institution study.13
We sought to develop a predictive model to identify
candidates for prostate biopsy based on multicenter data
using prebiopsy parameters to selectively discriminate risk
of histologically aggressive prostate cancer from no cancer
or histopathologically indolent cancer.
MATERIALS AND METHODS
The multicenter National Cancer Institute/Early Detec-
tion Research Network prostate cancer detection cohort is
a collaboration of several Early Detection Research Net-
work clinical validation centers that prospectively enroll
and follow men without prior diagnosis of prostate can-
cer. Men enrolled at 6 clinical practice sites at Harvard,
Michigan, and Cornell universities who had undergone
their first prostate biopsy were identified. As part of par-
ticipation in the Early Detection Research Network
cohort, all men had provided written informed consent,
and all prostate biopsies had been offered according to
National Comprehensive Cancer Network guidelines.14
Demographic and prebiopsy clinical data, including PSA
history, digital rectal examination (DRE) results, prostate
volume, and all biopsy procedure details were ascertained
on case report forms. All prostate biopsy results were
reviewed, with reports confirmed by institutional patholo-
gists. All pathology reports included confirmed histology,
number of cores, percentage of each core involved with
carcinoma, and primary and secondary Gleason patterns.
At the time of this analysis, the Early Detection Research
Network cohort database comprised 902 subjects who en-
rolled between June 2005 and December 2007, 635 of
whom had enrolled immediately before their first prostate
biopsy and had complete, quality-controlled demo-
graphic, clinical, and pathological data available. They are
the subject of this analysis. Furthermore, 236 Early Detec-
tion Research Network patients, enrolled January 2008
through April 2009, were also used to discern how many
biopsies could be avoided by using the proposed model.
Histologically aggressive prostate cancer was defined
by Epstein’s histopathologic criteria: Gleason score7, or
>3 cores positive, or 50% tumor involvement in any
individual core; all other cancers (Gleason score 6, 3
cores positive, and<50% tumor involvement in any core)
were deemed indolent.5
In the Early Detection Research Network analysis
cohort, demographic and prebiopsy clinical data were
compared between men with histologically aggressive
prostate cancer and men with indolent or no prostate can-
cer using Wilcoxon rank sum tests for continuous varia-
bles and Fisher exact tests for categorical variables.
Multivariate logistic regression models were fit that con-
sidered age, body mass index (BMI), race/ethnicity, fam-
ily history of prostate cancer, abnormal/suspicious DRE
result, PSA, prostate volume, and PSA density (PSAD ¼
PSA/[prostate volume]), the latter 3 risk factors with log-
transformation to improve fit of the model. Model selec-
tion was performed to identify and include only statisti-
cally significant risk factors at the .05 level of statistical
significance, in particular to identify the strongest predic-
tor among the highly correlated measures of PSA, prostate
volume, and PSAD. Individual risks of histologically
aggressive prostate cancer were calculated using the
inverse logistic function (exp[X0 b]/[1 þ exp(X0 b)]),
where X represents individual risk factors observed and b
represents the associated log odds ratios for the individual
risk factors estimated from the model. Discriminative
performance of these predicted risks were then compared
with 2 univariate models of PSA alone and PSAD alone
using the difference in the area under the receiver operat-
ing characteristic (ROC) curve (AUC) with bootstrap
95% confidence intervals (CIs), which provides an opti-
mistically biased internal validation because the same
data set was used to build the model underlying pre-
dicted risks.
Data from 3833 of 4734 participants in the control
arm of the Prostate Cancer Prevention Trial were used as
a validating generalization set for the Early Detection
Research Network prediction model. The Prostate Cancer
Prevention Trial study served as a generalization set,
because unlike the Early Detection Research Network
cohort, the Prostate Cancer Prevention Trial study was a
screening study of older healthy and primarily Caucasian
men with PSA <3.0 ng/mL and normal DRE required at
study entry, and Prostate Cancer Prevention Trial partici-
pants had a required end-of-study biopsy regardless of
PSA or DRE. PSA and DRE results either on the day of,
but before the biopsy, or within a maximum of 1 year
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before biopsy were used. Because of missing details about
biopsy cores, the definition of histologically aggressive
prostate cancer was modified to include greatest linear
extent of cancer (>5 mm as a surrogate for 50% tumor
involvement in a core). In total, 901 patients were
excluded because of missing BMI (0.9%), prostate vol-
ume (14%), or details about biopsy cores (5%). Sensitivity
analyses assessed the impact of this exclusion by repeating
the analysis using simple imputation of the median BMI
or prostate volume, and by considering any patient with
missing details about biopsy cores as having indolent can-
cer; the results were consistent and are not presented.
Evaluation of the Early Detection Research Network pre-
diction model was assessed by ROC AUC, with bootstrap
95% CIs, and by calibration comparing average model
risk and observed percentage with histologically aggressive
prostate cancer. All analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC).
RESULTS
Demographic and preclinical data of the 635 men under-
going first prostate biopsy as part of the Early Detection
Research Network analysis cohort are summarized in
Table 1. Three hundred sixty-one (57%) men had no can-
cer, whereas 88 (14%) and 186 (29%) patients were iden-
tified with indolent and histologically aggressive cancer,
respectively. Only 22 of 186 men diagnosed with histo-
logically aggressive prostate cancer had Gleason score 6
cancer with >3 cores positive or with at least 1 core con-
taining 50% cancer; all others had Gleason score 7
disease. In univariate analyses, men diagnosed with histo-
logically aggressive prostate cancer were significantly
older, had significantly higher PSA, smaller gland volume,
and higher PSAD, and more often had abnormal DRE
than men with indolent disease or no prostate cancer
(each P< .01).
In multivariate modeling, age, BMI, family history
of prostate cancer, abnormal DRE, and log of PSAD were
significant predictors of histologically aggressive cancer
(each P < .05) (Table 2). The AUC for model-predicted
risks was 0.81 (95% CI, 0.77-0.84) (Fig. 1). In contrast,
the AUCs for PSA only or PSAD only were 0.71 (95%
CI, 0.67-0.75) and 0.75 (95% CI, 0.71-0.80), respec-
tively. When compared with PSA alone, at a sensitivity
level of 90%, the multivariate model improved specificity
from 32% to 42%. The predicted probabilities of histo-
logically aggressive prostate cancer for a range of risk fac-
tor values are presented in Table 3. By using our model, of
the 236 Early Detection Research Network patients en-
rolled from January 2008 through April 2009, 24.6% of
biopsies could be avoided.
To assess the performance of the Early Detection
Research Network prediction model in identifying men
with histologically aggressive prostate cancer in the gen-
eral population, we applied the prediction model to the
Table 1. Demographic and Prebiopsy Clinical Characteristics of Men Undergoing First Prostate Biopsy for Prostate Cancer
Detection in the EDRN Analysis and PCPT Validation Cohorts, According to Biopsy Result
Characteristic EDRN Analysis Cohort, N5635 PCPT Validation Cohort, N53833
No Prostate
Cancer
Indolent
Prostate
Cancer
Histologically
Aggressive
Prostate
Cancer
No Prostate
Cancer
Indolent Prostate
Cancer
Histologically
Aggressive
Prostate
Cancer
Patients, No. (%) 361 (57) 88 (14) 186 (29) 3176 (83) 333 (9) 324 (8)
Age, y [IQR]a 60 [54-66] 61 [56-66] 64 [59-71] 69 [65-73] 69 [65-73] 69 [65-74]
BMI, kg/m2 [IQR] 27 [25-31] 27 [25-31] 27 [25-32] 27 [25-30] 27 [25-30] 27 [25-30]
Non-Caucasian, No. (%) 57 (16) 13 (15) 21 (11) 86 (3) 8 (2) 19 (6)
Family history of prostate
cancer, No. (%)
88 (24) 28 (32) 60 (32) 468 (15) 67 (20) 72 (22)
Abnormal DRE, No. (%)a 57 (16) 15 (17) 59 (32) 98 (3) 57 (17) 60 (15)
PSA, ng/mL [IQR]a 4.6 [3.0-6.0] 4.5 [3.4-6.0] 6.6 [4.8-9.0] 1.2 [0.7-2.0] 1.8 [1.0-2.9] 2.4 [1.5-4.0]
Prostate volume by
TRUS, cc [IQR]a
47 [35-65] 44 [35-58] 40 [31-55] 34 [26-45] 32 [25-42] 33 [25-43]
PSA density,
ng/mL/cc [IQR]a
0.09 [0.06-0.12] 0.10 [0.07-0.16] 0.16 [0.10-0.25] 0.03 [.02-.05] 0.05 [0.03-0.09] 0.07 [0.04-0.11]
Abbreviations: BMI, body mass index; DRE, digital rectal examination; EDRN, Early Detection Research Network; IQR, interquartile range; PCPT, Prostate Can-
cer Prevention Trial; PSA, prostate-specific antigen; TRUS, transrectal ultrasound.
aP < .01 in univariate comparison of histologically aggressive prostate cancer versus others; No. (%) compared using Fisher exact tests; or median [IQR] com-
pared using Kruskal-Wallis tests.
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control arm of the Prostate Cancer Prevention Trial
study. Among 3833 Prostate Cancer Prevention Trial
subjects, 324 (8%) had aggressive cancer on biopsy, 333
(9%) had indolent cancer, and the remainder had no
cancer. The model performed well in predicting aggres-
sive cancer (AUC, 0.78; 95% CI, 0.75-0.80). Although
predicted and observed probabilities of prostate cancer
diverged by overpredicting risk among patients at higher
risk for aggressive cancer, the model performance was
robust at lower levels of cancer risk (ie, risk <10%;
Table 4) and across most subgroups of the population
(Table 5), confirming the predictive accuracy of this
model in identifying men who can forego prostate
biopsy while retaining 90% sensitivity in detection of
aggressive cancer.
DISCUSSION
Stage migration related to widespread use of PSA screen-
ing has raised concerns regarding possible overdiagnosis
and overtreatment of prostate cancer.1,2,15 In the Early
Detection Research Network cohort, nearly 1=3 of biopsy-
detected cancers had histological features of indolent dis-
ease. Overtreatment of cancers that are diagnosed during
an indolent phase early in the course of the disease could
be averted by selective use of active surveillance.6-8,16-19
However, the use of active surveillance remains under-
used; definitive primary treatments are more commonly
being used, sometimes with adverse effects on quality of
life.2,20 Conversely, use of routine PSA cutoffs alone as a
decision point for identifying prostate biopsy can also lead
to underdiagnosis or nondiagnosis of cancers that are his-
tologically aggressive but have PSA levels below routine
thresholds. The use of simple PSA cutoffs as a sole focal
decision point for identifying candidates for prostate bi-
opsy has therefore been challenged by recent changes in
American Urological Association best practice recommen-
dations regarding prostate cancer screening and early
detection.21
Prostate biopsy does not come without inherent
risks, which include physical morbidity, emotional uncer-
tainty regarding being diagnosed with indolent cancer,
and cost to the health care system. Up to 2% of patients
undergoing prostate biopsy develop a febrile urinary tract
infection, bacteremia, or acute prostatitis requiring hospi-
talization, complicated by recent emergence of fluoroqui-
nolone resistance, among other possible biopsy-related
complications.22,23 The emotional sequelae of identifying
indolent cancer and the decision to undergo treatment or
active surveillance, as well as the cost of biopsy (approxi-
mately $347.24/man in the United States)24—together
with the unmeasured cost of cancers missed because of
Figure 1. Receiver operating characteristic curves are shown
for the multivariate prediction model (A) versus prostate-
specific antigen (PSA) alone (B) for predicting histologically
aggressive prostate cancer in the Early Detection Research
Network (EDRN) analysis cohort (n ¼ 635), and for the
model-predicted risks in the Prostate Cancer Prevention Trial
(PCPT) validation cohort (C; n ¼ 3833). In the EDRN cohort,
for a sensitivity of 90%, specificity was 42% versus 32% for
PSA; for a sensitivity of 80%, specificity was 60% versus 48%
for PSA (denoted by closed circles). AUC, area under the
ROC curve.
Table 2. Multivariate Model of Demographic and Prebiopsy Clinical Characteristics for the Presence of Histologically Aggressive
Prostate Cancer on First Prostate Biopsy in the Early Detection Research Network Analysis Cohort
Parameter Estimate Standard Error Odds Ratio (95% CI) P
Intercept 3.28 1.04 — —
Age per 10 years 0.54 0.12 1.72 (1.35-2.18) <.0001
BMI per 1 kg/m2 0.06 0.02 1.07 (1.02-1.11) .002
Family history of prostate cancer 0.82 0.23 2.27 (1.45-3.54) .0003
Abnormal DRE 1.08 0.25 2.95 (1.81-4.80) <.0001
Log PSA density per 1 U 1.51 0.17 4.51 (3.25-6.27) <.0001
Abbreviations: BMI, body mass index; CI, confidence interval; DRE, digital rectal examination; PSA, prostate-specific antigen.
Original Article
2654 Cancer May 15, 2012
underdiagnosis among some men with normal PSA lev-
els—further elevate societal costs of poorly discriminant
algorithms to identify candidates for prostate biopsy. Uro-
logical practice, patient outcomes, and cost effectiveness
of health care would each benefit from new targeted strat-
egies, such as nomograms that improve prediction of
aggressive cancers, to enable selective identification of
candidates for prostate biopsy that would improve the
yield of clinically significant, histologically aggressive can-
cers warranting subsequent definitive treatment.
Recognizing the value of avoiding unnecessary
biopsy by predicting individual probability of a prostate
cancer diagnosis, Thompson et al used data from the con-
trol arm of the Prostate Cancer Prevention Trial to
develop a prostate cancer risk calculator.12 The Prostate
Cancer Prevention Trial calculator uses a combination of
other risk factors with PSA (age, family history, and DRE)
to specify risk of prostate cancer before biopsy. The Pros-
tate Cancer Prevention Trial risk calculator was also used
for predicting high-grade cancers. However, the Prostate
Cancer Prevention Trial calculator has not been opti-
mized and validated specifically for the measurement of
risk of histologically aggressive disease as defined by the
Epstein criteria (which include amount of cancer on
Table 3. Predicted Probabilities for the Presence of Histologically Aggressive Prostate Cancer on First Prostate Biopsy Based on
the Early Detection Research Network Analysis Cohort, for a Range of Demographic and Prebiopsy Clinical Factors
Age, y Family
History of
Prostate
Cancer
BMI,
kg/m2
Normal DRE,
PSA Density, ng/mL/cc
Abnormal DRE,
PSA Density, ng/mL/cc
0.066 0.102 0.157 0.066 0.102 0.157
55 No 25 5.6 (3.6-8.6) 10.3 (7.2-14.6) 18.0 (13.1-24.3) 15.0 (9.2-23.3) 25.3 (16.9-36.1) 39.3 (27.9-52.0)
30 7.5 (5.1-11.0) 13.6 (9.9-18.3) 23.1 (17.5-29.8) 19.4 (12.4-29.0) 31.7 (21.9-43.3) 47.0 (34.7-59.7)
Yes 25 11.9 (7.8-17.7) 20.7 (14.6-28.4) 33.3 (24.6-43.2) 28.5 (18.3-41.5) 43.5 (30.6-57.3) 59.5 (45.3-72.3)
30 15.6 (10.9-21.9) 26.3 (19.6-34.2) 40.6 (31.5-50.3) 35.3 (23.8-48.8) 51.3 (37.8-64.6) 66.8 (53.1-78.2)
60 No 25 7.2 (4.9-10.6) 13.1 (9.7-17.5) 22.4 (17.3-28.4) 18.7 (12.3-27.6) 30.8 (21.8-41.4) 45.9 (34.7-57.6)
30 9.7 (6.9-13.3) 17.1 (13.3-21.7) 28.3 (22.7-34.6) 24.0 (16.2-33.9) 37.8 (22.7-49.0) 53.8 (42.0-65.2)
Yes 25 15.1 (10.2-21.7) 25.4 (18.6-33.8) 39.5 (30.3-49.5) 34.4 (23.1-47.8) 50.2 (37.0-63.4) 65.9 (52.4-77.2)
30 19.5 (14.0-26.6) 31.8 (24.5-40.2) 47.2 (37.9-56.8) 41.7 (29.3-55.3) 58.0 (44.6-70.2) 72.5 (60.0-82.3)
65 No 25 9.3 (6.4-13.2) 16.5 (12.5-21.4) 27.4 (21.8-33.9) 23.2 (15.7-32.9) 36.8 (27.1-47.7) 52.7 (41.4-63.7)
30 12.3 (9.0-16.6) 21.3 (16.9-26.4) 34.1 (28.0-40.7) 29.3 (20.5-39.9) 44.3 (33.7-55.5) 60.4 (48.9-70.8)
Yes 25 18.9 (12.8-26.9) 30.9 (22.7-40.5) 46.1 (35.9-56.7) 40.7 (28.0-54.7) 56.9 (43.3-69.6) 71.7 (58.8-81.7)
30 24.1 (17.3-32.7) 38.0 (29.3-47.5) 54.0 (43.8-63.9) 48.4 (35.0-62.1) 64.4 (51.0-75.8) 77.6 (66.0-86.1)
Abbreviations: BMI, body mass index; DRE, digital rectal examination; PSA, prostate-specific antigen.
The values are presented as percentages with 95% confidence intervals.
Values of age are approximately the 25th, 50th, and 75th percentiles of the distribution; values of BMI are approximately the 25th and 75th percentiles of the
distribution. Values of PSA density are the 25th, 50th, and 75th percentiles of the distribution.
Table 4. Comparison of Model-Predicted Risks With Observed Risks of Histologically Aggressive
Prostate Cancer in an Initial Prostate Biopsy in the Prostate Cancer Prevention Trial Validation
Cohort
Model-
Predicted
Risk
Range, %
Patients,
No.
Risk of Histologically
Aggressive Prostate Cancer
Mean Model-Predicted
Risk, %
Observed Percentage
of Patients
0.18 1.86 383 1.3 0.5
1.87 2.92 383 2.4 1.8
2.92 4.16 384 3.5 2.6
4.16 5.57 383 4.8 5.0
5.57 7.33 383 6.4 4.2
7.34 9.52 384 8.3 5.5
9.53 12.83 383 11.0 6.0
12.86 17.91 384 15.2 12.8
17.91 27.50 383 22.2 15.1
27.56 99.98 383 45.0 31.1
0.18 99.98 3833a 12.0 8.5
a All patients.
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biopsy), and does not provide the capability of consider-
ing high-volume Gleason score 6 cancers as aggressive
tumors, together with higher Gleason score cancers, as
proposed and validated by the model that we have devel-
oped in this study.
Postbiopsy, preprostatectomy nomograms have
been developed that used pathology findings at biopsy to
predict the probability of indolent prostate cancer at prosta-
tectomy.9,10 The Kattan postbiopsy nomogram used studied
sextant biopsy results in radical prostatectomy patients to
predict indolent disease at prostatectomy and was recali-
brated in a screening population from the European
Randomized Study on Screening for Prostate Cancer and in
a single-practice tertiary care US setting.9,10,25 Although
both nomograms predict indolent disease with adequate dis-
crimination, they require pathology results of prostate
biopsy to predict prostatectomy endpoints, and therefore
have limited utility in decision making regarding which
patients should undergo prostate biopsy in the first place.
With our predictive model, we propose bringing the strategy
of a predictive model upstream in the urological care pro-
cess, to help improve selection for men for prostate biopsy.
Nam et al previously demonstrated a multivariate
model of known prostate cancer risk factors to signifi-
cantly improve the positive predictive value of PSA.13 In
an attempt to individualize prostate cancer risk at the time
of first PSA and DRE, Nam et al developed a predictive
nomogram from men who underwent prostate biopsy.26
The nomogram incorporated age, ethnicity, family his-
tory of prostate cancer, presence of urinary symptoms,
total PSA, free:total PSA, and DRE to identify risk of
prostate cancer at first biopsy. The AUC for the nomo-
gram in predicting overall (0.74 vs 0.62) and specifically
high-grade cancer (0.77 vs 0.69) was significantly greater
than the AUC using PSA and DRE alone. Although the
nomogram proposed by Nam et al was an improved pre-
dictor for high-grade prostate cancer (Gleason score 7),
this criteria for identifying clinically significant disease
does not conform to the criteria previously identified by
Epstein. Moreover, the Prostate Cancer Prevention Trial
and Nam nomograms did not elucidate practical cut-
points or criteria based on the predictive models to guide
a specific decision as to when a biopsy may be averted.
Roobol et al have proposed an individualized screening
algorithm based on prebiopsy information by which
applying an additional biopsy cutoff of 12.5% would lead
to a 33% reduction in unnecessary biopsies.27
We found age, obesity (as measured by BMI), family
history, abnormal DRE, and PSAD as the principal fac-
tors associated with histologically aggressive cancer (all
P < .001). By using model-defined parameters at 90%
sensitivity to evaluate a subsequent cohort of 236 consecu-
tively enrolled men in the Early Detection Research Net-
work study, we found that 58 of 236 (24.6%) biopsies
would have been avoided. Averting 1=4 of prostate biopsies
while retaining 90% sensitivity for detecting aggressive
cancers as could be guided by this Early Detection
Research Network model would have the potential to sig-
nificantly reduce the burden of excess detection and treat-
ment of indolent prostate cancers.
Table 5. Comparison of Average Model-Predicted Risks With Observed Risks of Histologically Aggressive Prostate Cancer in an
Initial Prostate Biopsy Among Subgroups of the Prostate Cancer Prevention Trial Validation Cohort
Group Patients, No. Risk of Histologically Aggressive
Prostate Cancer
AUC (95% CI)
Mean Model-Predicted
Risk, %
Observed Percentage
of Patients
All 3833 12.0 8.5 0.78 (0.75-0.80)
Age <65 years 808 10.4 8.5 0.79 (0.74-0.84)
Age 65 years 3025 12.4 8.4 0.77 (0.75-0.80)
Caucasian 3720 12.0 8.2 0.77 (0.74-0.80)
Non-Caucasian 113 13.7 16.8 0.85 (0.75-0.94)
BMI <30 kg/m2 2827 11.4 8.4 0.77 (0.74-0.80)
BMI 30 kg/m2 1006 13.8 8.6 0.80 (0.75-0.85)
No family history 3226 10.3 7.8 0.79 (0.75-0.82)
Family history 607 21.2 11.9 0.73 (0.67-0.80)
Normal DRE 3628 10.9 7.6 0.77 (0.74-0.80)
Abnormal DRE 205 31.9 24.4 0.65 (0.56-0.73)
PSA density <0.102 ng/mL/cc 3518 9.3 6.5 0.74 (0.70-0.77)
PSA density 0.102 ng/mL/cc 315 42.7 30.8 0.58 (0.51-0.65)
Abbreviations: AUC, area under the curve; BMI, body mass index; CI, confidence interval; DRE, digital rectal examination; PSA, prostate-specific antigen.
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The association of the factors identified in the cur-
rent study with prostate cancer severity has been previ-
ously established in other settings, and supports the
external validity of our findings. Age, family history, and
DRE had also been found to be significant determinants
for presence or absence of cancer in the Prostate Cancer
Prevention Trial calculator.12 Of note, obesity as meas-
ured by BMI was a significant predictor for clinically sig-
nificant cancer, and this factor has not been included in
other tools used to discern indolent from aggressive
cancers.5,9,10,12,25 The relationship of obesity with aggres-
siveness of treated prostate cancers, however, is well estab-
lished, and with the increasing prevalence of obesity
worldwide, this variable may become ever more meaning-
ful in decision making during routine urological practice.
The biological basis for PSAD as predictive of cancer
severity is reflected by larger prostate being associated with
higher serum PSA because of PSA produced by benign
prostatic hyperplasia in the absence of any cancer.28-31
PSAD has previously been found to be superior to PSA
alone in discerning cancer from benign pathology in
patients with PSA between 4 and 10 ng/mL,29,30 and has
also been found to be associated with probability of recur-
rence-free survival after prostatectomy.29,30 Indeed, in his
initial report defining indolent cancers, Epstein deter-
mined that PSAD <0.1 ng/mL/g complemented histo-
logical criteria in predicting indolent cancer at
prostatectomy. Our observed association of PSAD with
detection of histologically aggressive cancer validates this
component of Epstein’s original findings and extends its
use, when combined with family history, age, DRE find-
ings, and BMI, to the identification of patients who are
candidates for initial prostate biopsy.
There are several limitations to our study. We used
Epstein’s original histological criteria to discern indolent
from aggressive cancers, and long-term clinical outcomes
of these patients to verify indolent behavior are limited.5,7
We used<5-mm tumor involvement per core in the Pros-
tate Cancer Prevention Trial cohort because actual per-
centage tumor involvement per core was not recorded,
and therefore we could not extrapolate percentage tumor
involvement per core. Prior studies have suggested the
role of percentage and tumor length in prostate biopsy
cores as predictors of more aggressive disease at radical
prostatectomy and hence clinically significant disease.32
Although our predictive model has not been externally
validated by others, the model was derived from multiple
institutions to avoid single-institution, practice-specific,
or regional biases, and was validated in the Prostate Can-
cer Prevention Trial study representing the general popu-
lation. Nevertheless, further external validation is
warranted to determine whether the model can be applied
to other clinical populations. Selection bias may be inher-
ent in our cohort, as enrollment focused on patients who
had been referred to a urology practice; therefore, our
findings are more relevant to decision making by urolo-
gists in evaluating patients referred from a primary care
provider than decision making in the primary care setting.
Our study did not include percentage free PSA, which has
been found to be associated with prostate cancer aggres-
siveness,11 because percentage free PSA is validated for use
only when total serum PSA is between 4 and 10 ng/mL,
whereas our model targets cancer detection across an
unrestricted spectrum of total PSA results. The patient
population has limited racial diversity, with 14% of men
self-reporting as non-Caucasian comprised of 7% African
American and 7% a mix of Hispanic, Asian, middle or
southeast Asian, and Cape Verdean, and an association of
race with aggressive cancer, independent of the other
model factors, was not detected; it is possible that racial
effects may be significant in more diverse study cohorts or
clinical settings. Overdiagnosis is a problem in prostate
cancer, and this could be addressed either by refining who
we biopsy or by better selection of patients for active sur-
veillance. The purpose of our study is to better identify
patients who may be harboring clinically significant pros-
tate cancer who may benefit from earlier intervention and
to improve current active surveillance selection protocols.
Finally, accepting a false-negative rate of 10%, thereby
avoiding 25% of biopsies, may be viewed as excessively
high. Up to 30% of men with insignificant cancer at first
biopsy ultimately are discovered to have significant cancer
(either at subsequent biopsy or surgery); thus, the real
false-negative rate could be much higher for the predictive
model. However, the strategy of avoiding biopsy at initial
evaluation does not preclude the possibility that patients
with false-negative initial screening results could be
detected during follow-up screening in subsequent years.
In light of these limitations, more extensive evaluation of
our model may be warranted to justify further broader
acceptance of averting biopsy.
Conclusions
Prior predictive nomograms or risk calculators have not
sought to identify men who should undergo prostate
biopsy with the goal of improving selective detection of
significantly aggressive prostate cancer, while avoiding
biopsy that would detect indolent disease. Our
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multivariate, predictive model improved the specificity
of PSA alone in detecting such histologically aggressive
cancers and elucidated practical cutpoints or criteria to
guide specific decision as to when a biopsy may be
averted while retaining 90% sensitivity for detection of
histologically aggressive prostate cancer. Generalizability
of these findings was verified in the control arm of the
Prostate Cancer Prevention Trial cohort. Our findings
suggest that 90% sensitivity for detecting significant can-
cer can be retained while averting prostate biopsy in men
who meet each of the following criteria: normal DRE,
no family history of prostate cancer, PSAD <0.1 ng/mL/
cc, and BMI <25 kg/m2. These criteria would avoid bi-
opsy in approximately 1=4 of biopsy-eligible men.
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